Boehringer Ingelheim

Brainomix develops AI-powered imaging biomarkers for neurological and cerebrovascular disorders. Its software suite, including e-ASPECTS, e-CTA, and e-Mismatch, automates brain scan analysis to assist physicians in making timely treatment decisions for stroke patients.

Refoxy Pharma develops therapeutic medicines aimed at treating age-related diseases and promoting healthy longevity. The company studies FOXO proteins that regulate genes involved in stress resistance and metabolism, and works on novel modulators of a central stress response pathway to influence aging through genetics, with the goal of extending the years of healthy living for patients.

Aignostics GmbH is a Berlin-based company founded in 2018 that specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics, employing patented technology to reverse-engineer conventional AI systems, thereby addressing their “black-box” limitations. Aignostics' platform generates explainable diagnostic results presented as precise heatmaps and image overlays, which facilitate the verification process for pathologists. This capability is crucial in ensuring accurate diagnoses, particularly in the context of discovering and validating biomarkers for cancer and other complex diseases. By improving the understanding of tissue-based biomarkers, Aignostics aims to significantly advance the diagnosis and treatment of various conditions, thereby supporting the broader goals of precision medicine and drug development.

Saiba Animal Health is a biotechnology company focused on developing therapeutic vaccines and drugs for chronic diseases in dogs and other companion animals. It aims to improve the well-being and quality of life of pets and their owners by advancing vaccination platforms that elicit long-lasting antibodies against key molecules that drive chronic conditions. The company’s recombinant virus-like particle platform is designed to target a range of disorders, including allergies, inflammation, pain, nervous system conditions and cancer, with the goal of mediating relief through disease modification and symptom management.

Nerio Therapeutics is a biotechnology company focused on the life sciences sector. It was founded in 2019 and is based in La Jolla, CA, USA.

Shengbao Bio is committed to the development of novel live bacterial medications, leveraging gene circuits and precise regulation of gene and payload expression.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

Asgard Therapeutics is a private biotechnology company focused on developing innovative cancer immunotherapies through direct cell reprogramming technologies. Founded as a spin-off from Lund University, the company employs its proprietary TrojanDC technology to initiate immune responses by leveraging the biological properties of professional antigen-presenting cells. With a commitment to creating personalized and efficient gene therapy products, Asgard Therapeutics aims to expand its pipeline of off-the-shelf cancer treatments, particularly for patients with cancers that are resistant to traditional therapies. By activating tailored anti-cancer immune defenses, the company seeks to offer new therapeutic options for individuals in need of effective cancer treatment alternatives.

Ilara Health develops and distributes AI-powered diagnostic devices for primary care doctors serving rural and peri-urban communities in Africa, with its headquarters in Nairobi, Kenya. The compact devices connect to a proprietary software platform and electronic medical records, recording patient data to support accurate, affordable diagnostics at the point of care. The company aims to expand access to essential diagnostics by targeting the highly fragmented primary care infrastructure and delivering devices directly to clinicians, enabling clinicians to deliver timely, data-backed diagnostic services.

T3 Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2015. The company focuses on the research and development of innovative bacteria-based therapies aimed at treating cancer patients. T3 Pharmaceuticals is committed to addressing the significant unmet need for novel cancer treatments by leveraging its proprietary protein delivery platform, which utilizes the bacterial type III secretion system. This approach enables the development of highly specific and efficient immuno-oncology therapies designed to target solid tumors. Through its work, T3 Pharmaceuticals aims to enhance the quality of life for cancer patients and improve treatment outcomes.

Glox Therapeutics specializes in developing precision antibiotic therapies derived from naturally occurring bacteriocins. Their focus is on targeting and eliminating specific, hard-to-treat gram-negative bacterial pathogens that are resistant to traditional antibiotics. By preserving the patient's microbiome, their approach aims to minimize side effects and provide a more balanced treatment strategy, thereby advancing the field of antimicrobial therapy.

Actym Therapeutics is a biotechnology company based in Berkeley, California. Founded in 2017, the company specializes in the discovery and development of novel immuno-oncology therapies to treat cancer. Actym's proprietary platform, STACT, uses attenuated bacteria to deliver multiplexed immunomodulatory payloads directly to tumor-resident immune cells, targeting intractable pathways with minimal systemic toxicities.

TeleVet, Inc. operates a mobile application designed to facilitate remote communication between pet owners and veterinarians. The application enables users to schedule virtual consultations, book follow-up appointments, and receive care through text, call, and video chat. It also supports veterinarians by providing tools for appointment scheduling, telemedicine services, and digital prescriptions, integrating seamlessly with existing veterinary practice management systems. Additionally, the app offers automated communication features, such as email templates and social media posts, to enhance client engagement regarding pet health services. Founded in 2015 and based in Austin, Texas, TeleVet, Inc. was previously known as Horse Facts, Inc. before rebranding in January 2016. The application is available for download on both the App Store and Google Play.

smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.

DiogenX is a French biotechnology company founded in 2019, focused on developing therapeutic solutions for diabetic patients. It specializes in pancreatic beta-cell modulators for treating Type 1 and Type 2 diabetes by regenerating insulin-producing cells.

Yale Cancer Center is a cancer treatment center that provides prevention, detection, diagnosis, and treatment for cancer. They provide treatments for patient care,oncology, and hematology.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

Aignostics GmbH is a Berlin-based company founded in 2018 that specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics, employing patented technology to reverse-engineer conventional AI systems, thereby addressing their “black-box” limitations. Aignostics' platform generates explainable diagnostic results presented as precise heatmaps and image overlays, which facilitate the verification process for pathologists. This capability is crucial in ensuring accurate diagnoses, particularly in the context of discovering and validating biomarkers for cancer and other complex diseases. By improving the understanding of tissue-based biomarkers, Aignostics aims to significantly advance the diagnosis and treatment of various conditions, thereby supporting the broader goals of precision medicine and drug development.

C-mo Medical Solutions specializes in developing innovative monitoring devices aimed at comprehensively assessing patients' cough patterns. The company's portable and ergonomic wearables are designed for long monitoring periods, allowing for extensive data collection on distinctive cough characteristics. Through fully automated analysis, these devices enable healthcare professionals to deliver accurate diagnoses and create personalized treatment plans for patients. C-mo's solutions address key use cases throughout the patient management lifecycle, ensuring that both patients and clinicians benefit from enhanced diagnostic capabilities in the realm of respiratory health.

Trutino Biosciences is a biopharmaceutical company focused on developing innovative cytokine therapies for cancer treatment. Founded in 2017 and based in San Diego, California, Trutino utilizes its proprietary On-Demand-Cytokine (ODC) platform technology to create therapeutic candidates that can be delivered in an inactive form, which are then activated locally at the tumor site. This approach aims to minimize the severe toxicity commonly associated with traditional cytokine therapies while potentially enhancing treatment efficacy, both as standalone therapies and in combination with other modalities. The company's immuno-oncology drugs are designed to specifically target and destroy cancer cells by stimulating tumor-specific immune responses, providing a promising avenue for improving patient outcomes in cancer care.

ArrePath is a biotechnology company focused on developing innovative therapies to combat drug-resistant infections. Its proprietary platform enables the creation of new medicines targeting multiple pathways, potentially enhancing efficacy and reducing development risks.

Centauri Therapeutics is a biotechnology company that develops novel immunotherapeutics employing a dual‑mechanism platform. Its molecules combine a cell‑surface antigen‑binding moiety with a glycan effector domain that harnesses the body’s pre‑existing polyclonal antibodies. This design amplifies complement fixation, antibody‑dependent cellular cytotoxicity, and phagocytosis, enabling targeted cell death. The company’s pre‑clinical studies demonstrate potent enhancement of complement fixation and opsonophagocytosis for both antibacterial and oncology agents, and in vivo proof of concept in multiple infection models. Centauri also utilizes alphamer technology, chemically synthesizing molecules that redirect endogenous antibodies to specific pathogens, providing a new approach to treating infectious diseases. The company focuses on life‑threatening conditions, aiming to bring innovative therapies to patients.

smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.

Brainomix develops AI-powered imaging biomarkers for neurological and cerebrovascular disorders. Its software suite, including e-ASPECTS, e-CTA, and e-Mismatch, automates brain scan analysis to assist physicians in making timely treatment decisions for stroke patients.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

Asgard Therapeutics is a private biotechnology company focused on developing innovative cancer immunotherapies through direct cell reprogramming technologies. Founded as a spin-off from Lund University, the company employs its proprietary TrojanDC technology to initiate immune responses by leveraging the biological properties of professional antigen-presenting cells. With a commitment to creating personalized and efficient gene therapy products, Asgard Therapeutics aims to expand its pipeline of off-the-shelf cancer treatments, particularly for patients with cancers that are resistant to traditional therapies. By activating tailored anti-cancer immune defenses, the company seeks to offer new therapeutic options for individuals in need of effective cancer treatment alternatives.

Optina Diagnostics is a diagnostics company focusing on retinal imaging and artificial intelligence to provide non-invasive tests that detect signs of neurodegenerative and ocular diseases. By analyzing retinal images, it identifies biomarkers associated with Alzheimer's disease, as well as eye conditions like age-related macular degeneration and diabetic retinopathy, enabling clinicians to assess brain health and disease risk early. The platform aims to support timely diagnosis and treatment decisions with a simple eye exam.

Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on the development of immuno-oncology therapeutics. Established in 2019, the company specializes in creating arenavirus-based drug candidates aimed at activating immune responses against cancerous tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's innovative approach to virotherapy seeks to harness the immune stimulation capabilities of arenaviruses, enabling the immune system to specifically target and eliminate malignant tumor tissue. Through its advanced therapeutic candidates, Abalos Therapeutics aims to provide new treatment options for cancer patients.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Dopavision GmbH, founded in 2017 and based in Berlin, Germany, specializes in developing a digital therapeutic aimed at treating myopia, commonly known as shortsightedness. This condition impacts approximately one in three individuals globally and has seen a significant rise in prevalence over the past two decades. The company's innovative approach involves delivering light stimulation to specific photosensitive cells in the retina, which helps modulate dopamine levels—a neurotransmitter crucial for regulating eye growth. By focusing on children and adolescents, Dopavision aims to create a clinically validated therapy that can effectively slow myopia progression. The therapeutic solution is designed to be seamlessly integrated with smartphone technology, allowing for an accessible and user-friendly treatment option.

xCures, Inc. is a healthcare technology company founded in 2018 and based in Los Altos, California, focused on transforming cancer treatment through its innovative AI-based precision oncology platform. The company addresses the challenges of traditional drug-centric treatment development by integrating cancer research and patient care. Its platform operates as a perpetual trial, continuously capturing Real World Evidence (RWE) from patients and treatments, allowing for real-time learning and adaptation. By coordinating treatment recommendations across various institutions, xCures ensures that patients receive personalized treatment options tailored to their specific needs. Additionally, the platform organizes insights from tumor boards, leveraging machine learning to assist healthcare professionals in making informed decisions. This approach not only enhances the effectiveness of cancer care but also aims to reduce the time and cost associated with drug development, ultimately improving patient outcomes.

Nuevocor is a preclinical-stage biopharmaceutical company dedicated to developing gene therapy-based treatments aimed at restoring cardiac function in hearts affected by disease. The company specializes in addressing genetic cardiomyopathies, which are characterized by abnormal mechanobiology. By focusing on modulating mechanical force transduction, Nuevocor seeks to provide innovative solutions that enable healthcare professionals to improve cardiac function in patients suffering from these conditions.

Founded in 2018 and based in Sheffield, UK, Rinri Therapeutics is a biotechnology company dedicated to developing regenerative stem cell-based therapies for treating hearing loss. Its innovative therapy aims to replace damaged sensory cells of the inner ear, restoring patients' hearing.

Delonix Bioworks develops biotechnology leveraging synthetic biology to design and engineer microbial strains for medicines and vaccines. The company focuses on next-generation, genetically engineered bacterial vaccines and related therapeutics to combat infectious diseases and antimicrobial-resistant infections, with an emphasis on improving vaccine research and expanding treatment options.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

NBE-Therapeutics GmbH is a privately owned biotechnology company based in Basel, Switzerland, founded in 2012. The company specializes in the development of antibody-drug conjugates (ADCs) aimed at treating cancer. NBE-Therapeutics focuses on creating innovative cancer therapies that enhance survival rates and improve the quality of life for patients worldwide. Its proprietary ADC platform is designed to produce potent and safe immune-stimulatory therapies that utilize an anthracycline payload. This approach not only targets tumor cells directly but also promotes a lasting immunological anti-tumor effect, positioning the company as a significant player in the oncology therapeutics field.

Labor Dr. Merk & Kollegen GmbH, established in 1971, specializes in providing high-quality diagnostic solutions for the medical field. The company has developed significant expertise in biotechnology, virology, microbiology, and toxicology, offering its knowledge to external clients, particularly in the pharmaceutical and medical device sectors. Labor Dr. Merk & Kollegen excels in biosafety testing, employing a variety of GMP and GLP compliant methods for preclinical studies and quality control of final products. Their services encompass contract manufacturing, process development, and testing in areas such as viral gene therapeutics, oncolytic viral therapeutics, vaccines, and immunology. The company prides itself on its highly qualified team, which offers personalized consultation throughout the study design and testing process, ensuring reliable and cost-effective solutions tailored to client needs.

Founded in 2017, Perfood is a German digital therapeutics startup that offers personalized nutrition-based therapies via an application. It focuses on weight management and migraine prevention by analyzing sensor data, lab results, and holistic analyses to derive tailored therapeutic solutions.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Ruipeng Pet Hospital, located in Shenzhen, specializes in a comprehensive range of pet care services. The hospital provides medical and beauty care for pets, including healthcare, foster care, bathing, SPA treatments, grooming, food, and entertainment. By offering both digital and clinical services, Ruipeng aims to ensure that pet owners can access high-quality care for their animals efficiently. The organization also includes online shopping options to further support pet owners in meeting their pets' needs.

Libra Therapeutics is a biotechnology company dedicated to developing novel disease-modifying therapeutics for neurodegenerative diseases. Its platform focuses on restoring cellular balance through small molecule drugs that attenuate the production of neurotoxic proteins, targeting conditions such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease.

Click Therapeutics is a New York‑based company that develops and commercializes digital therapeutics that use cognitive and neurobehavioral techniques to treat a range of medical conditions. Its platform personalizes treatment through an adaptive data science engine, aiming to improve engagement and clinical outcomes. The company’s flagship smoking‑cessation program has been approved for nationwide use and is available through payers, providers, and employers. It is also conducting a phase III FDA‑registered trial for a prescription digital therapy for major depressive disorder. Other indications under development include schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity. Founded in 2012, Click Therapeutics focuses on delivering software as a medical treatment that can be used independently or alongside conventional therapies.

Aignostics GmbH is a Berlin-based company founded in 2018 that specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics, employing patented technology to reverse-engineer conventional AI systems, thereby addressing their “black-box” limitations. Aignostics' platform generates explainable diagnostic results presented as precise heatmaps and image overlays, which facilitate the verification process for pathologists. This capability is crucial in ensuring accurate diagnoses, particularly in the context of discovering and validating biomarkers for cancer and other complex diseases. By improving the understanding of tissue-based biomarkers, Aignostics aims to significantly advance the diagnosis and treatment of various conditions, thereby supporting the broader goals of precision medicine and drug development.

Bodyport develops sensor-enabled scales and a home health platform to manage heart disease. The device measures blood pressure, heart rate, heart rate variability, arterial stiffness, and a health assessment via measurements from the feet, while the accompanying platform provides a biomarker-driven virtual clinic, online patient portal, and educational materials to support at-home care. The company integrates advanced sensors with proprietary algorithms to noninvasively capture hemodynamic biomarkers, delivering actionable insights for healthcare providers to assess overall patient status, enable timely interventions, and reduce hospitalizations. Incorporated in 2015 and based in San Francisco, Bodyport focuses on preventing and managing chronic cardiovascular conditions through digital therapeutics and remote monitoring.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Proxygen is a biotechnology company focused on developing innovative therapies for cancer and other life-threatening diseases. The company utilizes molecular glue degraders, a novel approach that targets and eliminates disease-causing proteins by reprogramming the natural protein recycling machinery present in cells. This method represents a significant shift from traditional therapies that merely inhibit harmful proteins. By harnessing advanced technology and expertise, Proxygen is pioneering the identification and development of novel glue degraders at scale, thus expanding the potential of the druggable target space. This positions Proxygen at the forefront of drug discovery, aiming to transform treatment options for incurable diseases.

Global Stem Cell Technology is a veterinary biotechnology company specializing in the development and production of advanced stem cell products for horses and dogs. The company focuses on blood-derived mesenchymal stem cells designed for clinical applications in animals, translating regenerative medicine into practical solutions. By prioritizing animal welfare, Global Stem Cell Technology aims to enhance the health and treatment options available for pets and equines through innovative stem cell therapies.

T3 Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2015. The company focuses on the research and development of innovative bacteria-based therapies aimed at treating cancer patients. T3 Pharmaceuticals is committed to addressing the significant unmet need for novel cancer treatments by leveraging its proprietary protein delivery platform, which utilizes the bacterial type III secretion system. This approach enables the development of highly specific and efficient immuno-oncology therapies designed to target solid tumors. Through its work, T3 Pharmaceuticals aims to enhance the quality of life for cancer patients and improve treatment outcomes.

DiogenX is a French biotechnology company founded in 2019, focused on developing therapeutic solutions for diabetic patients. It specializes in pancreatic beta-cell modulators for treating Type 1 and Type 2 diabetes by regenerating insulin-producing cells.

eTheRNA Immunotherapies NV is a Belgium-based biotechnology company that specializes in the development of mRNA-based immunotherapies. Founded in 2013 and located in Niel, the company focuses on harnessing the immune system's dendritic cells to create treatments for melanoma, triple-negative breast cancer, and infectious diseases. eTheRNA has developed innovative TriMix technology that enhances the immune response, enabling patients to better combat these diseases. The company aims to be a leader in nucleic acid-based medicines, collaborating with partners to facilitate the creation of new drugs and improve patient outcomes. Additionally, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its mission.

Northern Biologics Inc., established in 2014 and headquartered in Toronto, Canada, is an early-stage biologics company focused on developing antibody-based therapeutics for oncology and fibrosis. The company employs state-of-the-art phage display technology, originally developed at the University of Toronto, to discover novel therapeutic antibodies targeting challenging cancer and fibrosis pathways. Northern Biologics operates as a subsidiary of Boehringer Ingelheim International GmbH since May 2020, following its strategic collaboration with Celgene Corporation.

Wellth operates a mobile application that engages consumers in managing chronic diseases and fostering healthy habits. By providing targeted incentives, reminders, and information, Wellth aims to reduce healthcare costs by encouraging preventative actions and disease management.

Actym Therapeutics is a biotechnology company based in Berkeley, California. Founded in 2017, the company specializes in the discovery and development of novel immuno-oncology therapies to treat cancer. Actym's proprietary platform, STACT, uses attenuated bacteria to deliver multiplexed immunomodulatory payloads directly to tumor-resident immune cells, targeting intractable pathways with minimal systemic toxicities.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

NBE-Therapeutics GmbH is a privately owned biotechnology company based in Basel, Switzerland, founded in 2012. The company specializes in the development of antibody-drug conjugates (ADCs) aimed at treating cancer. NBE-Therapeutics focuses on creating innovative cancer therapies that enhance survival rates and improve the quality of life for patients worldwide. Its proprietary ADC platform is designed to produce potent and safe immune-stimulatory therapies that utilize an anthracycline payload. This approach not only targets tumor cells directly but also promotes a lasting immunological anti-tumor effect, positioning the company as a significant player in the oncology therapeutics field.

Eyevensys S.A.S. is a Paris-based company that specializes in non-viral gene therapy for ophthalmology. Founded in 2008, it focuses on developing innovative solutions to improve drug delivery methods for ocular diseases. The company utilizes its proprietary Electro-Transfection (ET) technology to administer plasmids to the ciliary muscle, allowing for the sustained release of therapeutic proteins directly into the vitreous, addressing conditions such as uveitis, age-related macular degeneration, and various retinopathies, including central retinal vein occlusion and diabetic retinopathy. Eyevensys aims to overcome the limitations of current treatment options, which often involve invasive procedures like intravitreal injections and surgeries. By enhancing compliance, ocular bioavailability, and tolerability, Eyevensys seeks to create a robust product pipeline that delivers improved clinical outcomes while minimizing the need for frequent and invasive interventions.

Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Its proprietary platform leverages computational biology, genomics, and metabolomics to identify specific metabolic alterations that support cancer growth. By creating small molecules that specifically target these reprogrammed metabolic processes, Metabomed aims to halt tumor progression while minimizing harm to surrounding healthy tissues. This innovative approach allows for quicker initiation of treatment and increases the likelihood of successful patient outcomes.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on the development of immuno-oncology therapeutics. Established in 2019, the company specializes in creating arenavirus-based drug candidates aimed at activating immune responses against cancerous tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's innovative approach to virotherapy seeks to harness the immune stimulation capabilities of arenaviruses, enabling the immune system to specifically target and eliminate malignant tumor tissue. Through its advanced therapeutic candidates, Abalos Therapeutics aims to provide new treatment options for cancer patients.

T3 Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2015. The company focuses on the research and development of innovative bacteria-based therapies aimed at treating cancer patients. T3 Pharmaceuticals is committed to addressing the significant unmet need for novel cancer treatments by leveraging its proprietary protein delivery platform, which utilizes the bacterial type III secretion system. This approach enables the development of highly specific and efficient immuno-oncology therapies designed to target solid tumors. Through its work, T3 Pharmaceuticals aims to enhance the quality of life for cancer patients and improve treatment outcomes.

Tacalyx GmbH is an oncology company based in Berlin, Germany, dedicated to the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies for cancer treatment. As a spin-off from the Max-Planck-Institute of Colloids and Interfaces, the company leverages advanced carbohydrate synthesis technology to produce highly pure TACA structures. These structures serve as novel targets for cancer therapies, addressing the tumor-specific expression of TACAs that results from aberrant glycosylation, which is linked to cancer progression, including metastasis and immune system suppression. Tacalyx aims to develop innovative therapeutics that enhance the effectiveness of immunotherapies by triggering robust anti-cancer responses through the synthesis and identification of antibodies targeting these carbohydrate antigens.

Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.

Dopavision GmbH, founded in 2017 and based in Berlin, Germany, specializes in developing a digital therapeutic aimed at treating myopia, commonly known as shortsightedness. This condition impacts approximately one in three individuals globally and has seen a significant rise in prevalence over the past two decades. The company's innovative approach involves delivering light stimulation to specific photosensitive cells in the retina, which helps modulate dopamine levels—a neurotransmitter crucial for regulating eye growth. By focusing on children and adolescents, Dopavision aims to create a clinically validated therapy that can effectively slow myopia progression. The therapeutic solution is designed to be seamlessly integrated with smartphone technology, allowing for an accessible and user-friendly treatment option.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

Founded in 2018 and based in Sheffield, UK, Rinri Therapeutics is a biotechnology company dedicated to developing regenerative stem cell-based therapies for treating hearing loss. Its innovative therapy aims to replace damaged sensory cells of the inner ear, restoring patients' hearing.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

ICD Therapeutics is a privately held MacroDel biologics-delivery platform developer.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.

ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients.

Wellth operates a mobile application that engages consumers in managing chronic diseases and fostering healthy habits. By providing targeted incentives, reminders, and information, Wellth aims to reduce healthcare costs by encouraging preventative actions and disease management.

MabVax Therapeutics is a clinical stage biopharmaceutical company dedicated to the development and commercialization of innovative anti-cancer immunotherapies. The company leverages two main technology platforms: one involves proprietary vaccines developed at Memorial Sloan-Kettering Cancer Center, with two lead cancer vaccines currently in Phase II clinical trials targeting soft tissue sarcoma and ovarian cancer, both of which have received substantial federal grant support. The second platform is an internally developed human antibody discovery system, which focuses on the immune responses from patients who have been vaccinated against specific cancers. MabVax's leading human antibody candidate is in preclinical evaluation for potential applications in treating colon, pancreatic, and breast cancers, also backed by federal funding. The company aims to address significant unmet needs in cancer treatment through its innovative approaches and pipeline of human monoclonal antibody products.

NBE-Therapeutics GmbH is a privately owned biotechnology company based in Basel, Switzerland, founded in 2012. The company specializes in the development of antibody-drug conjugates (ADCs) aimed at treating cancer. NBE-Therapeutics focuses on creating innovative cancer therapies that enhance survival rates and improve the quality of life for patients worldwide. Its proprietary ADC platform is designed to produce potent and safe immune-stimulatory therapies that utilize an anthracycline payload. This approach not only targets tumor cells directly but also promotes a lasting immunological anti-tumor effect, positioning the company as a significant player in the oncology therapeutics field.

Acousia Therapeutics GmbH is a biotechnology company based in Tübingen, Germany, focused on developing innovative treatments for hearing loss. Established in 2012, the company specializes in identifying small molecules that can be applied locally to protect or restore hearing function. Acousia's approach centers on stimulating the regeneration of sensory hair cells in the inner ear, which are crucial for hearing. This regenerative capability is achieved by leveraging supporting cells that can replace lost hair cells. The company's therapeutic candidates aim to address hearing loss caused by various factors, such as noise exposure, ototoxic medication, and sudden deafness, and also hold potential for treating age-related hearing decline.

Brainomix develops AI-powered imaging biomarkers for neurological and cerebrovascular disorders. Its software suite, including e-ASPECTS, e-CTA, and e-Mismatch, automates brain scan analysis to assist physicians in making timely treatment decisions for stroke patients.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

Aelin Therapeutics is a privately held Belgian biotherapeutics company founded in 2017, based in Heverlee. The company develops antibiotics and therapeutics using its proprietary Pept-in technology, which leverages protein aggregation to induce functional knockdown of target proteins. This approach allows for the rational design of novel biotherapeutics that can address undruggable human targets and combat resistant bacteria like Methicillin-resistant Staphylococcus aureus (MRSA). Aelin Therapeutics' platform offers a unique mode of action and intracellular target space, differentiating it from traditional small molecule drugs or protein-based therapeutics. The company's technology has shown applications in various areas including bacteria, cancer cells, fungi, viruses, and plant cells, with supporting preclinical Proof of Concept data published in high-impact journals such as Science.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

Sentien Biotechnologies, Inc. is a clinical-stage biotechnology company focused on developing innovative cell therapies aimed at restoring immune system balance and improving treatment options for patients with systemic inflammatory diseases. The company specializes in proprietary cell compositions and Good Manufacturing Practice (GMP) manufacturing methods that enhance the efficacy of cell therapy. Its flagship product, SBI-101, utilizes an extracorporeal device to immobilize Mesenchymal Stromal Cells (MSCs), facilitating sustained and controlled delivery of their therapeutic properties, which include anti-inflammatory and regenerative effects. Additionally, the company offers the Sentinel device, designed to treat patients during dialysis by supplementing their blood with MSC-derived secretions that address immune dysfunction and promote tissue repair. Founded in 2008, Sentien Biotechnologies is headquartered in Medford, Massachusetts.

Sentieon, Inc. is a bioinformatics company based in Mountain View, California, founded in 2014. It specializes in developing and commercializing cloud-based solutions for the life sciences and clinical markets. Sentieon offers a range of bioinformatics tools designed for processing genomics data with a focus on accuracy, efficiency, and quick turnaround times. Its notable products include Sentieon DNAseq, which aids in germline DNA analysis, and Sentieon TNseq, designed for detecting tumor-normal somatic variants. These software-only tools boast scalability and upgradeability, leveraging optimized algorithms to improve computing performance. Sentieon aims to enhance the capabilities of scientists and clinicians by providing precision tools that facilitate comprehensive tumor characterization and other critical bioinformatics processes.

Merial Limited is an animal healthcare company focused on the research, development, and production of pharmaceutical products and vaccines for livestock, pets, and wildlife. The company offers a range of products, including anesthetics, antiparasitics, antimicrobials, and vaccines designed to combat various diseases, such as Newcastle Disease and Avian Flu. Notable products include IVOMEC, used for parasite treatment in cattle, sheep, and swine, and FRONTLINE, which is designed for dogs and cats. Merial serves a diverse clientele, including veterinarians, pet owners, farmers, and food animal producers globally. Founded in 1997 as a joint venture between the animal health assets of Rhône-Poulenc and Merck & Co., the company is headquartered in Duluth, Georgia, and operates in numerous countries worldwide. Merial Limited is now a subsidiary of Sanofi-Aventis, following the acquisition of Rhône-Poulenc and Merck's stake in the company.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

Acousia Therapeutics GmbH is a biotechnology company based in Tübingen, Germany, focused on developing innovative treatments for hearing loss. Established in 2012, the company specializes in identifying small molecules that can be applied locally to protect or restore hearing function. Acousia's approach centers on stimulating the regeneration of sensory hair cells in the inner ear, which are crucial for hearing. This regenerative capability is achieved by leveraging supporting cells that can replace lost hair cells. The company's therapeutic candidates aim to address hearing loss caused by various factors, such as noise exposure, ototoxic medication, and sudden deafness, and also hold potential for treating age-related hearing decline.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

NBE-Therapeutics GmbH is a privately owned biotechnology company based in Basel, Switzerland, founded in 2012. The company specializes in the development of antibody-drug conjugates (ADCs) aimed at treating cancer. NBE-Therapeutics focuses on creating innovative cancer therapies that enhance survival rates and improve the quality of life for patients worldwide. Its proprietary ADC platform is designed to produce potent and safe immune-stimulatory therapies that utilize an anthracycline payload. This approach not only targets tumor cells directly but also promotes a lasting immunological anti-tumor effect, positioning the company as a significant player in the oncology therapeutics field.

Promethera Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases. Founded in 2009 and based in Mont-Saint-Guibert, Belgium, with an office in Tokyo, Japan, the company specializes in cell therapy products, notably HepaStem and H2Stem, which utilize allogeneic progenitor cells derived from healthy human adult livers. Promethera is actively working on treatments for a range of conditions, including acute-on-chronic liver failure, hemophilia, liver fibrosis, non-alcoholic steatohepatitis, liver-based metabolic diseases, and urea cycle disorders. The company also engages in strategic alliances to further its research and development efforts, enhancing its capacity to discover and commercialize effective cell therapies for liver-related ailments.

Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.

STAT-Diagnostica is a company dedicated to the development of near-patient testing products aimed at enhancing healthcare delivery. It specializes in creating point-of-care diagnostic devices designed for rapid turnaround applications and critical care environments. The company's flagship product, DiagCORE, is a portable multi-analyte instrument that supports both molecular and immunoassay testing across various clinical settings. By integrating multiple testing techniques into a single device, STAT-Diagnostica enables healthcare professionals to streamline patient care and improve diagnostic efficiency.

Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Its proprietary platform leverages computational biology, genomics, and metabolomics to identify specific metabolic alterations that support cancer growth. By creating small molecules that specifically target these reprogrammed metabolic processes, Metabomed aims to halt tumor progression while minimizing harm to surrounding healthy tissues. This innovative approach allows for quicker initiation of treatment and increases the likelihood of successful patient outcomes.

Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.

eTheRNA Immunotherapies NV is a Belgium-based biotechnology company that specializes in the development of mRNA-based immunotherapies. Founded in 2013 and located in Niel, the company focuses on harnessing the immune system's dendritic cells to create treatments for melanoma, triple-negative breast cancer, and infectious diseases. eTheRNA has developed innovative TriMix technology that enhances the immune response, enabling patients to better combat these diseases. The company aims to be a leader in nucleic acid-based medicines, collaborating with partners to facilitate the creation of new drugs and improve patient outcomes. Additionally, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its mission.